Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 20, 2024 9:34pm

109 Views

Post# 35890064

RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

February 20, 2024 - Forbes -

Back On Track: Biopharmaceutical Sector Sees M&A Revival

"The biopharmaceutical sector has experienced a revival in mergers and acquisitions in the second half of the year. I see three primary reasons for this uptick in deal-making intensity: patent expiration, pharmaceutical companies seeking pipeline diversity as a consequence of the Inflation Reduction Act and the availability of cash on Big Pharma’s balance sheets, among other factors."

"In the current macroeconomic environment, where the cost of capital remains quite high and the number of IPOs is diminishing, Big Pharma is still ready to pay a premium for the acquisition of companies with promising pipelines or even separate molecules."

"Even with increased regulatory scrutiny, I still see room for potentially larger deals. Companies with a market capitalization of up to $50 billion may become possible targets."

https://www-forbes-com.cdn.ampproject.org/v/s/www.forbes.com/sites/forbesfinancecouncil/2024/01/03/back-on-track-biopharmaceutical-sector-sees-ma-revival/amp/?amp_gsa=1&amp_js_v=a9&usqp=mq331AQIUAKwASCAAgM%3D#amp_tf=From%20%251%24s&aoh=17084821917606&referrer=https%3A%2F%2Fwww.google.com&ampshare=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fforbesfinancecouncil%2F2024%2F01%2F03%2Fback-on-track-biopharmaceutical-sector-sees-ma-revival%2F

<< Previous

Bullboard Posts

Next >>

High Tide adds two stores to undervalued cannabis retail network